<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lederman, Lynne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">De Santis, Maria</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Treatment Challenges in Genitourinary Cancer Require Additional Clinical Trial Data</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">25-26</style></pages><abstract><style  face="normal" font="default" size="100%">Treatment of advanced genitourinary cancers remains challenging. This article provides updates in genitourinary oncology addressed some important questions in the field that need answers to improve patient outcomes. Specific topics include clinical trial data for the currently approved agents, unresectable bladder cancer, as well as the treatment of metastatic renal cell carcinoma.</style></abstract><number><style face="normal" font="default" size="100%">36</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>